Overview

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Status:
Completed

Trial end date:
2004-07-01

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring the incidence of total response of nausea and vomiting and/or retching following administration of moderate-to-high emetogenic chemotherapeutic agents.

Phase:

Phase 3

Details

Lead Sponsor:

Solvay Pharmaceuticals

Treatments:

Dronabinol
Ondansetron